Atrial fibrillation (AF) and congestive heart failure (CHF) are two of the major cardiovascular challenges facing humanity in this century. Studies have shown that atrial fibrillation and heart failure often coexist, atrial fibrillation was first diagnosed, 26% of patients had or coexisted with heart failure, and 16% of patients may develop heart failure; while heart failure was first diagnosed, 24% of patients had or coexisted with atrial fibrillation, and 17% of patients later developed atrial fibrillation, and the proportion of combined atrial fibrillation increased significantly with increasing cardiac function NYHA classifications. Combined atrial fibrillation in heart failure with dilated cardiomyopathy is a challenge in the management of cardiovascular disease, and the incidence of combined atrial fibrillation in heart failure will increase progressively with the aging of the population and the prevalence of other cardiovascular diseases. Although transcatheter ablation has progressed from paroxysmal to persistent AF, and three-dimensional labeling technology has become increasingly sophisticated, standardized pharmacological therapy remains the foundation for improving symptoms and prognosis in patients with dilated cardiomyopathy heart failure combined with atrial fibrillation, including ACEI/ARBs, beta blockers, and anticoagulant therapy. Non-pharmacologic therapy is an important alternative treatment for patients with unsatisfactory results of pharmacologic therapy. The results of existing studies suggest that transcatheter radiofrequency ablation to reset and maintain sinus rhythm can significantly improve symptoms and cardiac function in patients with heart failure combined with atrial fibrillation. Because most of the types of AF in these patients are persistent and often have multiple comorbidities, the experience of medical centers and clinicians in AF ablation is critical to the efficacy and safety of the procedure. Dilated heart disease is one of the most persistent diseases in heart disease, and it is often combined with atrial fibrillation, which aggravates their heart failure; therefore, the treatment of atrial fibrillation in dilated heart disease is a necessary measure to improve their prognosis. The dangers of combined atrial fibrillation in dilated heart disease are intricately related to the relationship between heart failure and atrial fibrillation. Both share common pathologic factors, and both heart failure causes atrial fibrillation and atrial fibrillation causes and exacerbates hemodynamic changes in patients with heart failure. Numerous reports indicate that irregularities in the cardiac cycle decrease cardiac output and increase perfusion pressure. Furthermore, rapid ventricular rates may exacerbate heart failure and occasionally lead to cardiomyopathy.